Biotech manager is on life support

Thu Mar 29, 2007



A struggling biotech hedge fund has offered to waive management fees in exchange for a longer lockup and higher performance fees after a year of sliding returns.

The arrangement has helped New York-based Mallette Capital Management keep onshore and offshore versions of Mallette Capital Biotech Fund open despite a 27% loss in November that dragged its full-year return down by 40%.

Biotech...

ISSN: 2151-1845 / CDC10004H

Free Trial



Take a trial today and access

  • Performance news, fund launches, regulation changes and people moves
  • Profiles of fund managers, investors and distributors
  • Live league tables
  • Investor mandates



Popular Searches on HFI